REV1-POL ζ Inhibition and Cancer Therapy

Area of Science:

• Molecular Biology
• Cancer Research
• Drug Discovery

Background:

• Mutagenic translesion DNA synthesis is crucial for cancer cell survival under genotoxic stress.
• The interaction between REV1 and REV7 proteins is a key component of this pathway.
• Targeting this interaction presents a potential therapeutic strategy.

Purpose of the Study:

• To identify and characterize a small-molecule inhibitor targeting the REV1-REV7 interaction.
• To evaluate the efficacy of this inhibitor in sensitizing cancer cells to cisplatin.
• To assess the inhibitor's effect on mutagenesis in vitro and in vivo.

Main Methods:

• Small-molecule screening and characterization.
• In vitro and in vivo cancer cell-based assays.
• Assessment of DNA damage and repair pathways.
• Mutagenesis assays.

Main Results:

• A novel small-molecule inhibitor specifically targeting the REV1-REV7 interaction was identified.
• The inhibitor demonstrated significant sensitization of cancer cells to cisplatin in both in vitro and in vivo models.
• Treatment with the inhibitor led to a reduction in mutagenesis.

Conclusions:

• Inhibition of the REV1-REV7 interaction is a viable strategy to enhance cisplatin chemotherapy.
• This approach can overcome treatment resistance and reduce secondary mutagenic events in cancer therapy.